(VTRS) Viatris - Ratings and Ratios

Viatris Inc. is a global healthcare company with a diverse portfolio of pharmaceutical products and services, operating in multiple regions including North America, Europe, and Asia. The companys business is segmented into Developed Markets, Greater China, JANZ, and Emerging Markets, allowing for a nuanced approach to different markets. Viatris offers a range of prescription brand drugs, generic drugs, complex generic drugs, and biosimilars, addressing various therapeutic areas such as cardiovascular, CNS and anesthesia, dermatology, and oncology.

The companys product offerings are extensive, with medications available in various forms, including oral solid doses, injectables, and complex dosage forms. Viatris distributes its products through multiple channels, including pharmaceutical wholesalers and distributors, retailers, institutional pharmacies, and specialty pharmacies. The companys brands, such as Lyrica, Lipitor, and Celebrex, are well-established in the market, and its collaboration agreements with other companies, like Mapi Pharma Ltd. and Revance Therapeutics, Inc., demonstrate its commitment to developing and commercializing new products.

From a technical analysis perspective, Viatris stock price is currently at $8.46, with its 20-day SMA at $8.62 and 50-day SMA at $8.24, indicating a potential short-term trend reversal. The stocks 200-day SMA is at $10.45, suggesting a longer-term downtrend. The ATR of 0.31 represents a 3.62% daily volatility, which is relatively moderate. Considering the 52-week high and low of $13.02 and $7.16, respectively, the stock is currently trading near its lower end of the range.

Combining the technical analysis with fundamental data, we can observe that Viatris has a market capitalization of $10.22 billion and a forward P/E ratio of 3.98, indicating a relatively low valuation. However, the companys RoE of -20.60% raises concerns about its profitability. Based on these factors, a potential forecast is that Viatris stock price may experience a short-term bounce due to its oversold condition, but its long-term performance will depend on the companys ability to improve its profitability and effectively manage its diverse portfolio of products and collaborations.

Taking into account the current technical and fundamental data, a possible trading strategy could be to monitor the stocks price action around the $8.24 level, as a break above this level could indicate a potential buying opportunity. Conversely, a drop below the 52-week low of $7.16 could signal further downside. Investors should closely watch the companys future earnings reports and announcements regarding its collaborations and product developments to reassess their investment decisions.